Corticotropin-releasing factor induces a place aversion independent of its neuroendocrine role

doi:10.1016/0006-8993(92)91487-Y

Brain Research

Volume 597, Issue 2, 4 December 1992, Pages 304-309

https://doi.org/10.1016/0006-8993(92)91487-Y Get rights and content

Abstract

The purpose of the present experiment was to test the hypothesis that corticotropin-releasing factor (CRF), a polypeptide of 41 amino acids, when administered either intracerebroventricularly (i.c.v.) or subcutaneously (s.c.), has aversive properties in the conditioned place-preference paradigm. Five doses of CRF (0, 0.005, 0.05, 0.5, 5 μg) were tested. i.c.v. CRF induced a specific dose-dependent reduction of the amount of time spent in the environment previously paired with the administration of CRF. Furthermore, this CRF-induced place aversion was prevented by pretreatment with α-helical-CRF(9–41), a specific CRF antagonist, administered i.c.v. In order to test whether the aversive effects induced by i.c.v. CRF could result from the stimulation of the HPA axis accompanying i.c.v. CRF injection, the reinforcing properties of s.c. CRF were studied using the same dose range. Only the higher s.c. dose was effective in producing a place aversion suggesting that the aversive effects of CRF could not be due solely to the stimulation of the pituitary-adrenocortical system, measured by plasmatic levels of adrenocorticotropic hormone (ACTH) and corticosterone, because the lower doses consistently activate the pituitary-adrenocortical system without producing any behavioral changes. Altogether, these data indicate that the non-neurosecretory CRF neurons may mediate the aversive state occurring during stress.

References (38)

C.W. Berridge et al.
Corticotropin-releasing factor elicits naloxone sensitive stress-like alterations in exploratory behavior in mice
Regul. Pept.
(1986)
D.R. Britton et al.
Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty
Life Sci.
(1982)
M.R. Brown et al.
Corticotropin-releasing factor: physiological regulator of adrenal epinephrine secretion
Brain Res.
(1985)
A.J. Dunn et al.
Corticotropin releasing-factor administration elicits a stress-like activation of cerebral catecholaminergic systems
Pharmacol. Biochem. Behav.
(1987)
A.J. Dunn et al.
Physiological and behavioral responses to corticotropin releasing factor: is CRF a mediator of anxiety or stress responses?
Brain Res. Rev.
(1990)
C.L. Ehlers et al.
Corticotropin-releasing factor produces increases in brain excitability and convulsive seizures in rats
Brain Res.
(1983)
L.A. Fisher
CRF: endocrine and autonomic integration of responses to stress
TIPS
(1989)
L.A. Fisher et al.
Corticotropin-releasing factor (CRF): mechanisms to elevate mean arterial pressure and heart rate
Regul. Pept.
(1983)
B.A. Gosnell et al.
A comparison of the effects of Corticotropin-Releasing Factor and sauvagine on food intake
Pharmacol. Biochem. Behav.
(1983)
S.C. Heinrichs et al.
Both conditioned taste preference and aversion induced by corticotropin-releasing factor
Pharmacol. Biochem. Behav.
(1991)

M. Jouhaneau-Bowers et al.

ACTH self-administration in rats

Pharmacol. Biochem. Behav.

(1979)

N.H. Kalin et al.

Fear motivated behavior induced by prior shock experience is mediated by CRF systems

Brain Res.

(1990)

N.H. Kalin et al.

Antagonism of endogenous CRH systems attenuates stress-induced freezing behavior in rats

Brain Res.

(1988)

J.E. Morley et al.

CRF, grooming and ingestive behavior

Life Sci.

(1982)

D.J.S. Sirinathsinghji

Inhibitory influence of corticotropin-releasing factor on components of sexual behavior in the male rat

Brain Res.

(1987)

L. Stinus et al.

Nucleus accumbens and amygdala are possible substrates for the aversive stimulus effects of opiate withdrawal

Neuroscience

(1990)

A. Tazi et al.

Corticotropin releasing factor antagonist blocks stress-induced fighting in rats

Regul. Pept.

(1987)

M. Amalric et al.

Rewarding properties of β-endorphin as measured by conditioned place preference

Psychopharmacology

(1987)

H.A. Baldwin et al.

Behavioral effects of CRF

Cited by (63)

Central CRF and acute stress differentially modulate probabilistic reversal learning in male and female rats
2021, Behavioural Brain Research
Citation Excerpt :
However, this neuropeptide and its cognate receptors are also widely expressed in brain regions that reside outside of HPA axis circuitry [25–27]. As a consequence, increased CRF activity in other brain regions can by itself mediate many of the cognitive effects of stress [28–30]. Similar to acute stress, central infusion of exogeneous CRF impairs attention and working memory in male rats [31,32].
Acute stress can have variable and sometimes sex-dependent effects on different executive functions, including cognitive flexibility, some of which may be mediated by increased corticotropin releasing factor (CRF). Previous studies on the effects of stress and CRF on cognitive flexibility have used procedures entailing deterministic rewards, yet how they may alter behavior when outcomes are probabilistic is unclear. The present study examined how acute stress and increased CRF activity alters probabilistic reversal learning (PRL) in male and female rats. Rats learned to discriminate between a ‘correct’ lever rewarded on 80 % of trials, and an “incorrect” lever delivering reward on 20 % of trials, with reward contingencies reversed after 8 consecutive correct choices. Separate groups received either intracerebroventricular infusions of CRF (3 μg) or restraint stress prior to a PRL session. Experiments examined how these manipulations affected learning when given prior to a one-day acquisition test or during performance in well-trained rats. Exogenous CRF, and to a lesser extent acute stress, impaired motivation across sexes, slowing deliberation times and increasing the number of trials omitted, particularly following a switch in reward contingencies. Neither manipulation significantly altered errors or reversal performance. However, increased CRF activity reduced negative feedback sensitivity. Across manipulations, females showed increased omissions and choice latencies, and were less sensitive to feedback than males. These results reveal the complexity with which stress, CRF, sex, and experience interact to alter aspects of motivation and probabilistic reinforcement learning and provide insight into how CRF activity may contribute to symptoms of stress-related disorders.
The role of pituitary adenylyl cyclase-activating polypeptide in the motivational effects of addictive drugs
2020, Neuropharmacology
Citation Excerpt :
However, further studies are needed to identify the site of regulatory action of PACAP. Given that PACAP increases the expression of corticotropin releasing hormone (CRH, also known as CRF) in the paraventricular nucleus (PVN) of the hypothalamus (Agarwal et al., 2005; Grinevich et al., 1997; Stroth et al., 2011) and CRH elicits aversion (Cador et al., 1992) as well as taste aversion (Benoit et al., 2000) in rodents, we hypothesize that PACAP may be acting at the level of PVN to mediate the aversive effects of nicotine. Alternatively, PACAP may be acting in the habenula to alter the aversive effect of nicotine (Fig. 1).
Pituitary adenylyl cyclase activating polypeptide (PACAP) was originally isolated from the hypothalamus and found to stimulate adenylyl cyclase in the pituitary. Later studies showed that this peptide and its receptors (PAC1, VPAC1, and VPAC2) are widely expressed in the central nervous system (CNS). Consistent with its distribution in the CNS, the PACAP/PAC1 receptor system is involved in several physiological responses, such as mediation of the stress response, modulation of nociception, regulation of prolactin release, food intake, etc. This system is also implicated in different pathological states, e.g., affective component of nociceptive processing, anxiety, depression, schizophrenia, and post-traumatic stress disorders. A review of the literature on PubMed revealed that PACAP and its receptors also play a significant role in the actions of addictive drugs. The goal of this review is to discuss the literature regarding the involvements of PACAP and its receptors in the motivational effects of addictive drugs. We particularly focus on the role of this peptide in the motivational effects of morphine, alcohol, nicotine, amphetamine, methamphetamine, and cocaine.
This article is part of the special issue on Neuropeptides.
The role of endogenous pituitary adenylyl cyclase activating polypeptide (PACAP) in nicotine self-administration, reward and aversion
2019, Pharmacology Biochemistry and Behavior
Pituitary adenylyl cyclase activating polypeptide (PACAP) and its receptors (PAC1, VPAC1, and VPAC2) are localized in brain regions implicated in stress response, reward seeking and aversive responses, raising the possibility that PACAP may be involved in motivational effects of nicotine. To test this hypothesis, we used two-bottle choice (TBC) and place conditioning paradigms and assessed if nicotine preference or conditioned place preference (CPP) or aversion (CPA) induced by nicotine would be altered in mice lacking PACAP compared to their wild-type controls. In the TBC paradigm, mice had access to two water bottles during the first week and then one of the water bottles was switched to nicotine solution (20, 40 and then 80 μg/mL). The volume of water and nicotine consumed was measured every day. In the place conditioning paradigm, mice were tested for baseline place preference on day 1, received conditioning with saline versus a low (0.25) or high (1 mg/kg) dose nicotine and, respectively, tested for CPP or CPA 24 h following the last conditioning. We discovered that mice lacking PACAP compared to their wild-type controls exhibited more preference for nicotine over water in the TBC paradigm, particularly at the two higher concentrations of nicotine. While the rewarding action of the low dose nicotine was not altered in mice lacking PACAP, the aversive effect of the high dose nicotine was blunted in these mice compared to their wild-type controls. The present results suggest that endogenous PACAP may play a functional role in nicotine preference and its aversive effect.
Corticotropin-releasing factor in ventromedial prefrontal cortex mediates avoidance of a traumatic stress-paired context
2017, Neuropharmacology
Citation Excerpt :
Brain CRF is dysregulated in psychiatric disorders including anxiety disorders, depression, and drug use disorders (George and Koob, 2010). Central administration of CRF increases anxiety-like behaviors and autonomic stress responses (Dunn and Berridge, 1990; Fisher, 1989), and produces conditioned place aversion (Cador et al., 1992). CRF1 receptors (CRFR1) mediate anxiety-like behavior and hyperarousal in stressed rats (Heinrichs and Koob, 2004; Roltsch et al., 2014).
Post-traumatic stress disorder (PTSD) affects 7.7 million Americans. One diagnostic criterion for PTSD is avoidance of stimuli that are related to the traumatic stress. Using a predator odor stress conditioned place aversion (CPA) model, rats can be divided into groups based on stress reactivity, as measured by avoidance of the odor-paired context. Avoider rats, which show high stress reactivity, exhibit persistent avoidance of stress-paired context and escalated alcohol drinking. Here, we examined the potential role of corticotropin-releasing factor (CRF), a neuropeptide that promotes anxiety-like behavior in mediating avoidance and escalated alcohol drinking after stress. CRF is expressed in the medial prefrontal cortex (mPFC). The dorsal and ventral sub-regions of the mPFC (dmPFC and vmPFC) have opposing roles in stress reactivity and alcohol drinking. We hypothesized that vmPFC CRF-CRFR1 signaling contributes functionally to stress-induced avoidance and escalated alcohol self-administration. In Experiment 1, adult male Wistar rats were exposed to predator odor stress in a CPA paradigm, indexed for avoidance of odor-paired context, and brains processed for CRF-immunoreactive cell density in vmPFC and dmPFC. Post-stress, Avoiders exhibited higher CRF cell density in vmPFC, but not the dmPFC. In Experiment 2, rats were tested for avoidance of a context repeatedly paired with intra-vmPFC CRF infusions. In Experiment 3, rats were stressed and indexed, then tested for the effects of intra-vmPFC CRFR1 antagonism on avoidance and alcohol self-administration. Intra-vmPFC CRF infusion produced avoidance of a paired context, and intra-vmPFC CRFR1 antagonism reversed avoidance of a stress-paired context, but did not alter post-stress alcohol self-administration. These findings suggest that vmPFC CRF-CRFR1 signaling mediates avoidance of stimuli paired with traumatic stress.
The Nociceptin Receptor as an Emerging Molecular Target for Cocaine Addiction
2016, Progress in Molecular Biology and Translational Science
Cocaine addiction is a global public health and socioeconomic issue that requires pharmacological and cognitive therapies. Currently there are no FDA-approved medications to treat cocaine addiction. However, in preclinical studies, interventions ranging from herbal medicine to deep-brain stimulation have shown promise for the therapy of cocaine addiction. Recent developments in molecular biology, pharmacology, and medicinal chemistry have enabled scientists to identify novel molecular targets along the pathways involved in drug addiction. In 1994, a receptor that showed a great deal of homology to the traditional opioid receptors was characterized. However, endogenous and exogenous opioids failed to bind to this receptor, which led scientists to name it opioid receptor-like receptor, now referred to as the nociceptin receptor. The endogenous ligand of NOPr was identified a year later and named orphanin FQ/nociceptin. Nociceptin and NOPr are widely distributed throughout the CNS and are involved in many physiological responses, such as food intake, nociceptive processing, neurotransmitter release, etc. Furthermore, exogenous nociceptin has been shown to regulate the activity of mesolimbic dopaminergic neurons, glutamate, and opioid systems, and the stress circuit. Importantly, exogenous nociceptin has been shown to reduce the rewarding and addictive actions of a number of drugs of abuse, such as psychostimulants, alcohol, and opioids. This paper reviews the existing literature on the role of endogenous nociceptin in the rewarding and addictive actions of cocaine. The effect of exogenous nociceptin on these processes is also reviewed. Furthermore, the effects of novel small-molecule NOPr ligands on these actions of cocaine are discussed. Overall, a review of the literature suggests that NOPr could be an emerging target for cocaine addiction pharmacotherapy.
Serotonergic versus nonserotonergic dorsal raphe projection neurons: Differential participation in reward circuitry
2014, Cell Reports
The dorsal raphe nucleus (DRN) contains the largest group of serotonin-producing neurons in the brain and projects to regions controlling reward. Although pharmacological studies suggest that serotonin inhibits reward seeking, electrical stimulation of the DRN strongly reinforces instrumental behavior. Here, we provide a targeted assessment of the behavioral, anatomical, and electrophysiological contributions of serotonergic and nonserotonergic DRN neurons to reward processes. To explore DRN heterogeneity, we used a simultaneous two-vector knockout/optogenetic stimulation strategy, as well as cre-induced and cre-silenced vectors in several cre-expressing transgenic mouse lines. We found that the DRN is capable of reinforcing behavior primarily via nonserotonergic neurons, for which the main projection target is the ventral tegmental area (VTA). Furthermore, these nonserotonergic projections provide glutamatergic excitation of VTA dopamine neurons and account for a large majority of the DRN-VTA pathway. These findings help to resolve apparent discrepancies between the roles of serotonin versus the DRN in behavioral reinforcement.

View all citing articles on Scopus

View full text

Research reportCorticotropin-releasing factor induces a place aversion independent of its neuroendocrine role

Abstract

Regul. Pept.

Life Sci.

Brain Res.

Pharmacol. Biochem. Behav.

Brain Res. Rev.

Brain Res.

TIPS

Regul. Pept.

Pharmacol. Biochem. Behav.

Pharmacol. Biochem. Behav.

Pharmacol. Biochem. Behav.

Brain Res.

Brain Res.

Life Sci.

Brain Res.

Neuroscience

Regul. Pept.

Rewarding properties of β-endorphin as measured by conditioned place preference

Psychopharmacology

Behavioral effects of CRF

Research report
Corticotropin-releasing factor induces a place aversion independent of its neuroendocrine role